The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research. The Ipsen Life Sciences Program will, for a period of up to five years, sponsor three categories of research programs through targeted, core and innovation grants.
Ipsen will provide funding for targeted research programs carried out at the Salk Institute by researchers in the field of proliferative diseases with a particular emphasis on novel therapeutic concepts for the treatment of pituitary adenomas. Core grants will support basic research on the contribution of chronic inflammation to malignant diseases such as cancer, loss of cognitive functions, movement disorders and metabolic syndromes. Innovation grants will fund the exploration of advanced scientific concepts.
Jean-Luc Belingard, chairman and CEO of Ipsen, said: “This agreement confirms Ipsen’s commitment to innovation and research, and reaffirms the company’s capacity to work with worldwide academic centers of excellence, both in Europe and in the US, to transform knowledge into therapies.”